Ottimo Pharma

Ottimo Pharma is a UK-based, private, clinical-stage biotech focused on innovative immuno-oncology therapeutics. Its core technology is a platform for developing dual-paratopic antibodies, with a lead asset, OTP-01 (Jankistomig), targeting PD-1 and VEGFR2 simultaneously in a single agent. The company has strong leadership with deep industry experience from companies like Seagen, Novartis, and Pfizer, and has achieved key milestones including FDA IND clearance and first patient dosing in a Phase I/IIa study. Ottimo is positioned to address a significant unmet need in cancers responsive to PD-1 and VEGF pathway inhibition.

Platform for developing dual-paratopic antibodies, enabling a single antibody to bind two distinct epitopes. Lead application targets PD-1 and VEGFR2 simultaneously.

Competition is intense from established PD-1/VEGF combination therapies (e.g., Keytruda + Lenvima) and a pipeline of next-generation immuno-oncology agents from large pharmaceutical companies. Ottimo's differentiation hinges on demonstrating superior efficacy, safety, or convenience with its single-agent, dual-paratopic approach.